2004
DOI: 10.1002/jcp.20128
|View full text |Cite
|
Sign up to set email alerts
|

Regulation of proliferation and migration in retinoic acid treated C3H10T1/2 cells by TGF‐β isoforms

Abstract: (1) while all three TGF-beta isoforms stimulate chemotaxis/chemokinesis of multipotent C3H10T1/2 cells, TGF-beta1 and -beta3 do not stimulate chemotaxis in C3H10T1/2 cells treated with ATRA while TGF-beta2 stimulated chemotaxis only at the highest concentration tested. (2) TGF-beta isoforms do not appear to stimulate cell proliferation in C3H10T1/2 cells in either a multipotent state or after ATRA treatment when expressing higher levels of alkaline phosphatase and collagen type I gene markers. (3) Decrease in … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
14
1
1

Year Published

2005
2005
2020
2020

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 23 publications
(19 citation statements)
references
References 59 publications
3
14
1
1
Order By: Relevance
“…When we analyzed the transcription of single receptor types, we found that RA treatment of either CLP-SP fibroblasts or N-SP cells downregulated TGFBR1, upregulated TGFBR2, and did not affect TGFBR3 gene expression. Although a previous study (49) reported RA decreases mRNA expression of TGF-β receptors, the significance of our differing results with each receptor is impossible to establish within the scope of the present study. In the final analysis, RA treatment of both CLP-SP and N-SP fibroblasts appears to modulate TGF-β3 system activity, which could account for the altered ECM composition (less GAG and FN production) that we found in RA-treated cells.…”
Section: Discussioncontrasting
confidence: 72%
“…When we analyzed the transcription of single receptor types, we found that RA treatment of either CLP-SP fibroblasts or N-SP cells downregulated TGFBR1, upregulated TGFBR2, and did not affect TGFBR3 gene expression. Although a previous study (49) reported RA decreases mRNA expression of TGF-β receptors, the significance of our differing results with each receptor is impossible to establish within the scope of the present study. In the final analysis, RA treatment of both CLP-SP and N-SP fibroblasts appears to modulate TGF-β3 system activity, which could account for the altered ECM composition (less GAG and FN production) that we found in RA-treated cells.…”
Section: Discussioncontrasting
confidence: 72%
“…Thus, the functional motility characteristics we found for cells in our study agree with the fluorescence-activated cell sorting (FACS) profiling of the human cells indicating that these bone marrow-derived MSCs display an uncommitted phenotype, as is the case for marrow-derived MSCs from human and rabbit in the absence of exogenous osteogenic factors (51,66). Furthermore, our results suggest that at least rabbit and human cells have a similar motogenic behavior, and do not display the interspecies cytokine-induced motogenic variability that has been seen when comparing mice, rat, and human MSCs for TGF-␤ (16,43,44,65), an inconsistency that has also been reflected with other nonosteogenic fibroblastic cells (48).…”
Section: Fig 4 Dose-response For Haptotaxis Of Rabbit and Humansupporting
confidence: 52%
“…The parallel use of rabbit and human cells was judged necessary on the basis of previous literature suggesting interspecies extrapolation to be misleading. The in vitro variability of phenotype markers such as alkaline phosphatase production and osteoinduction potential comparing MSCs from different species can be significant (42), as can chemotaxis comparing mice/rat (17,43,44) and human (16) MSCs, using conserved factors such as transforming growth factor-␤ (TGF␤1) and fibroblast growth factor-2 (FGF-2).…”
Section: Introduction Mmentioning
confidence: 99%
“…20 Cells (2.5×10 4 in 100 μL) were plated in triplicate onto Costar transwell membranes in the serum-free HMSCGM with 0.1% bovine serum albumin. Lower chambers contained HMSCGM with 1% fetal bovine serum (FBS).…”
Section: Methodsmentioning
confidence: 99%